Alzheimer's disease is usually associated with old age. But around 5%-10% of all Alzheimer's cases occur in people under the age of 65. Early-onset ...
A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...
A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...
“The benefits of Kisunla were not large enough to outweigh the risks of potentially fatal events,” the agency said, citing ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.
Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...
To determine the underlying causes of neuronal vulnerability at the earliest stages of Alzheimer's Disease (AD), a research ...
For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback